Second Primary Lung Cancer Cohort Study (SPORT)

  • Research type

    Research Study

  • Full title

    Second Primary Lung Cancer Cohort Study (SPORT)

  • IRAS ID

    265946

  • Contact name

    Robert Rintoul

  • Contact email

    robert.rintoul@nhs.net

  • Sponsor organisation

    Royal Papworth Hospital NHS Foundation Trust

  • Duration of Study in the UK

    4 years, 11 months, 31 days

  • Research summary

    Patients who have had curative treatment for lung cancer are at an increased risk of developing second primary lung cancers (and other cancers) over the next 10 years. Doctors need to develop better ways of monitoring patients during follow up so we can intervene as quickly as possible with further treatments. Measuring DNA in the blood which has come from the tumour, so called circulating tumour DNA or ctDNA, may be one way to do this. Recent technological advances suggest that we can measure very low levels of ctDNA from small tumours.
    We plan to recruit 850 patients who have had previous surgery or radiotherapy with curative intent for lung cancer between 2 and 5 years previously and ask them to provide a blood sample every six months for the next five years. Information from their routine clinical care along with any x-rays and blood tests will be collected. For patients who do develop a second primary cancer we will collect additional blood samples and ask for a sample of the new biopsy specimen taken as part of their clinical management. We recognise that some patients will develop a recurrence of their first cancer, rather than a second primary cancer, during this time and we will be able to study this relapse using the same type of samples.
    Going forward our aim is to develop new special blood tests looking at ctDNA and other factors which can be used in conjunction with standard clinical follow-up to try and identify patients at the earliest stage who are at highest risk for either recurrent disease or a second primary cancer. In the future this will allow us to intervene at an early stage with treatments for those patients at highest risk thereby improving survival rates.

  • REC name

    London - Surrey Borders Research Ethics Committee

  • REC reference

    19/LO/1477

  • Date of REC Opinion

    31 Oct 2019

  • REC opinion

    Further Information Favourable Opinion